Reading HUMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HUMA free→
Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Watch· this week
$1.07+1.42%
Close 2026-06-15 · 1-day change
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 426% below where it trades (it looks expensive on this basis); the read is rich, as it trades above peer multiples, and the longer horizon does not make that back through growth. If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting HUMA and other Healthcare names. This read is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $284.47M
- Employees
- —
- IPO date
- 2020-08-04
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $1.07. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryexpensive
$0.16consensus
Range $0.13 – $0.18
vs price: +589% above
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-year—
—consensus
Range — – —
vs price: —
Method agreement —
Embeds projected growth. Leans optimistic by design. Upside context.
5-year—
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Optionality premiumlow confidence
At $1.07, HUMA's earnings are too small for P/E to mean much; on sales it trades at 95× p/s (10.1× the 9× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $0.20 fair value covers only the as-is business, low confidence. Not investment advice.
Multiple (P/S)
94.8x
peer 9.4x · own history —
Premium
10.1x peer
Growth the price needs
441%
our forecast —
Our fair value
$0.20
range $0.20 – $0.20
WhyPeer anchor understates a real premiumOptionality our model can't price
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
expensiverich12-month view
What's priced in
The market is pricing in roughly 441% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Elevated fragilityrisk posture, not a price call
Flags: expensive valuation, a turbulent sector regime (Heating).
Historical context
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
33rd pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 1.04x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
Management & capital allocation
volatile14 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bullishEPS revised +8.2% / 30d, n=3for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.11 → $-0.10 (+8.2% / 30d). 1 raised, 1 cut, 3 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 4 maintained. 80% of analysts rate Buy.
Material events
1 positive, 0 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weakProvisional
- Capital allocation
- weak
- Earnings discipline
- neutral
- Margin discipline
- weak
- Post-call reaction
- weak
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-15
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$541.
How much price usually moves either way.
On a bad day, this stock has moved -$962.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,896.
Deepest peak-to-trough drop in the last year.
elevatedas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceMonthsactive 4d
Watch for details on the underwritten offering
Why it matters: The offering could provide needed capital for growth and operations. It may signal confidence in future prospects.
What confirms / what disproves
Confirms:A press release says the offering raised more than $50 million.
Disproves:The offering fails to raise the expected amount or is delayed beyond the planned timeline.
Material event
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for HUMA yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VRTX, REGN, and ARGX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting HUMA and other Healthcare names. Worth watching these names for early signals.
- If HUMA beats again next quarter like it did this past one (a big beat of +26% on the 2026-03-31 print), the momentum tends to extend, with Street estimates ratcheting up and the stock typically following.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for HUMA and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like VRTX, REGN, and ARGX start missing or guiding lower, the Healthcare tailwind helping HUMA and other Healthcare names could fade. Watch these names for early warning.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits HUMA and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-06-116d agoItem 1.01
Entry into a Material Definitive Agreement. On June 10 , 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”), pursuant to which the Company agreed to is…
M&A activitypositive
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-9.0 vs last weeklatest as of 2026-06-16
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.